QCM
TGTX icon

Qsemble Capital Management’s TG Therapeutics TGTX Stock Holding History

Qsemble Capital Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-27,053
Closed -$806K – 626
2025
Q4 		$806K Sell
27,053
-18,571
-41% -$607K 0.07% 310
2025
Q3 		$1.65M Buy
45,624
+34,437
+308% +$1.13M 0.16% 190
2025
Q2 		$403K Sell
11,187
-20,609
-65% -$767K 0.04% 344
2025
Q1 		$1.25M Buy
+31,796
New +$1.07M 0.13% 203

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Qsemble Capital Management's TGTX Position: Q1 2026 in Review

Qsemble Capital Management sold out of TG Therapeutics (TGTX) in Q1 2026, closing a stake of 27,053 shares — an estimated $806K sold.

Qsemble Capital Management first reported a position in TGTX in Q1 2025 and held it in 4 quarters. The position peaked at $1.65M in Q3 2025. 364 funds tracked by Wall St. Rank hold TGTX as of Q1 2026.

  • Qsemble Capital Management reported no remaining TG Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Qsemble Capital Management sold 27,053 TG Therapeutics shares in Q1 2026, an estimated $806K.
  • Qsemble Capital Management first reported a position in TG Therapeutics in Q1 2025 and held it in 4 quarters.
  • Qsemble Capital Management's TG Therapeutics position peaked at $1.65M in Q3 2025.
  • 364 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2026.

Based on Qsemble Capital Management's 13F filing for Q1 2026, filed 7 May 2026.